Key Takeaways RHHBY's sales grew 7% in 2025 at constant exchange rates on strong demand for drugs and diagnostics.Roche Pharmaceuticals sales rose 9% on strong demand for Ocrevus, Hemlibra, Vabysmo, Xolair and Phesgo.RHHBY expects mid-single-digit 2026 sales growth at CER and progress from new approvals and pipeline.Swiss pharma giant Roche Holding AG's (RHHBY) 2025 results were affected by currency headwinds.Sales totaled $74.4 billion, which missed the Zacks Consensus Estimate of$81.4 billion. Earnings p ...